

Mercedes Gonzalez-juarrero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4332632/publications.pdf>

Version: 2024-02-01

53
papers

3,101
citations

218677

26
h-index

168389

53
g-index

54
all docs

54
docs citations

54
times ranked

4212
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in <i>Mycobacterium abscessus</i> . <i>Science Translational Medicine</i> , 2022, 14, eabj3860.	12.4	15
2	Lipid nanoparticle formulation of niclosamide (nano NCM) effectively inhibits SARS-CoV-2 replication in vitro. <i>Precision Nanomedicine</i> , 2021, 4, 724-737.	0.8	11
3	Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. <i>ACS Infectious Diseases</i> , 2021, 7, 2850-2863.	3.8	8
4	Unique Features of <i>Mycobacterium abscessus</i> Biofilms Formed in Synthetic Cystic Fibrosis Medium. <i>Frontiers in Microbiology</i> , 2021, 12, 743126.	3.5	11
5	Inhaled tigecycline is effective against <i>Mycobacterium abscessus</i> in vitro and in vivo. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1889-1894.	3.0	16
6	Neonatal and infant immunity for tuberculosis vaccine development: importance of age-matched animal models. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	2.4	7
7	Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. <i>Pharmaceutical Research</i> , 2019, 36, 136.	3.5	19
8	Minipigs as a neonatal animal model for tuberculosis vaccine efficacy testing. <i>Veterinary Immunology and Immunopathology</i> , 2019, 215, 109884.	1.2	9
9	Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice. <i>Tuberculosis</i> , 2019, 114, 119-122.	1.9	8
10	Sterilization of <i>Mycobacterium tuberculosis</i> infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. <i>Tuberculosis</i> , 2019, 117, 52-55.	1.9	2
11	Direct Inhibition of MmpL3 by Novel Antitubercular Compounds. <i>ACS Infectious Diseases</i> , 2019, 5, 1001-1012.	3.8	74
12	Host Directed Therapy for Chronic Tuberculosis via Intrapulmonary Delivery of Aerosolized Peptide Inhibitors Targeting the IL-10-STAT3 Pathway. <i>Scientific Reports</i> , 2018, 8, 16610.	3.3	25
13	Optimization and Lead Selection of Benzothiazole Amide Analogs Toward a Novel Antimycobacterial Agent. <i>Frontiers in Microbiology</i> , 2018, 9, 2231.	3.5	28
14	Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 1895.	3.5	5
15	Evidence of zoonotic leprosy in Par�ı, Brazilian Amazon, and risks associated with human contact or consumption of armadillos. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006532.	3.0	65
16	<i>Yersinia pestis</i> Survival and Replication in Potential Ameba Reservoir. <i>Emerging Infectious Diseases</i> , 2018, 24, 294-302.	4.3	27
17	Cell mediated immune response in goats after experimental challenge with the virulent <i>Brucella melitensis</i> strain 16M and the reduced virulence strain Rev. 1. <i>Veterinary Immunology and Immunopathology</i> , 2018, 202, 74-84.	1.2	9
18	Interactions of free-living amoebae with rice bacterial pathogens <i>Xanthomonas oryzae</i> pathovars <i>oryzae</i> and <i>oryzicola</i> . <i>PLoS ONE</i> , 2018, 13, e0202941.	2.5	22

#	ARTICLE	IF	CITATIONS
19	The minipig as an animal model to study <i>Mycobacterium tuberculosis</i> infection and natural transmission. <i>Tuberculosis</i> , 2017, 106, 91-98.	1.9	23
20	<i>Mycobacterium bovis</i> hosted by free-living amoebae permits their long-term persistence survival outside of host mammalian cells and remain capable of transmitting disease to mice. <i>Environmental Microbiology</i> , 2017, 19, 4010-4021.	3.8	21
21	Evaluation of shedding, tissue burdens, and humoral immune response in goats after experimental challenge with the virulent <i>Brucella melitensis</i> strain 16M and the reduced virulence vaccine strain Rev. 1. <i>PLoS ONE</i> , 2017, 12, e0185823.	2.5	36
22	Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. <i>Advanced Drug Delivery Reviews</i> , 2016, 102, 21-32.	13.7	20
23	Therapeutic Potential of the <i>Mycobacterium tuberculosis</i> Mycolic Acid Transporter, MmpL3. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5198-5207.	3.2	99
24	Presence of multiple lesion types with vastly different microenvironments in C3HeB/FeJ mice following aerosol infection with <i>Mycobacterium tuberculosis</i> . <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 591-602.	2.4	127
25	Partial Saturation of Menaquinone in <i>Mycobacterium tuberculosis</i> : Function and Essentiality of a Novel Reductase, MenJ. <i>ACS Central Science</i> , 2015, 1, 292-302.	11.3	71
26	Long-term Survival and Virulence of <i>Mycobacterium leprae</i> in Amoebal Cysts. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3405.	3.0	78
27	GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against <i>Mycobacterium abscessus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1057-1064.	3.0	49
28	Spectinomides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. <i>Nature Medicine</i> , 2014, 20, 152-158.	30.7	160
29	Microhemorrhage is an early event in the pulmonary fibrotic disease of PECAM-1 deficient FVB/n mice. <i>Experimental and Molecular Pathology</i> , 2014, 97, 128-136.	2.1	6
30	Reduced in vitro immune response on titania nanotube arrays compared to titanium surface. <i>Biomaterials Science</i> , 2013, 1, 322-332.	5.4	66
31	Experimental aerosol <i>Mycobacterium bovis</i> model of infection in goats. <i>Tuberculosis</i> , 2013, 93, 558-564.	1.9	22
32	Polar Lipids of <i>Burkholderia pseudomallei</i> Induce Different Host Immune Responses. <i>PLoS ONE</i> , 2013, 8, e80368.	2.5	7
33	Mouse Model for Efficacy Testing of Antituberculosis Agents via Intrapulmonary Delivery. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3957-3959.	3.2	25
34	Immunity to TB and targets for immunotherapy. <i>Immunotherapy</i> , 2012, 4, 187-199.	2.0	19
35	Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells. <i>Tuberculosis</i> , 2011, 91, 86-92.	1.9	25
36	Local pulmonary immunotherapy with siRNA targeting TGF β 1 enhances antimicrobial capacity in <i>Mycobacterium tuberculosis</i> infected mice. <i>Tuberculosis</i> , 2011, 91, 98-106.	1.9	50

#	ARTICLE	IF	CITATIONS
37	Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. <i>Journal of Leukocyte Biology</i> , 2010, 88, 159-168.	3.3	101
38	Intrapulmonary Delivery of XCL1-Targeting Small Interfering RNA in Mice Chronically Infected with <i>Mycobacterium tuberculosis</i> . <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2009, 41, 136-145.	2.9	60
39	Immune Response to <i>Mycobacterium tuberculosis</i> and Identification of Molecular Markers of Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2009, 40, 398-409.	2.9	34
40	Lack of IL-10 alters inflammatory and immune responses during pulmonary <i>Mycobacterium tuberculosis</i> infection. <i>Tuberculosis</i> , 2009, 89, 149-157.	1.9	89
41	Localized Immunosuppressive Environment in the Foreign Body Response to Implanted Biomaterials. <i>American Journal of Pathology</i> , 2009, 175, 161-170.	3.8	161
42	Relative Levels of M-CSF and GM-CSF Influence the Specific Generation of Macrophage Populations during Infection with <i>Mycobacterium tuberculosis</i> . <i>Journal of Immunology</i> , 2008, 180, 4892-4900.	0.8	57
43	Interleukin-10 Promotes <i>Mycobacterium tuberculosis</i> Disease Progression in CBA/J Mice. <i>Journal of Immunology</i> , 2008, 181, 5545-5550.	0.8	198
44	Animal Models of <i>M. tuberculosis</i> Infection. <i>Current Protocols in Microbiology</i> , 2007, 7, Unit 10A.5.	6.5	11
45	Enhanced Macrophage Activity in Granulomatous Lesions of Immune Mice Challenged with <i>Mycobacterium tuberculosis</i> . <i>Journal of Immunology</i> , 2006, 176, 4931-4939.	0.8	40
46	Factors Associated with Severe Granulomatous Pneumonia in <i>Mycobacterium tuberculosis</i> -Infected Mice Vaccinated Therapeutically with hsp65 DNA. <i>Infection and Immunity</i> , 2005, 73, 5189-5193.	2.2	36
47	Foamy Macrophages within Lung Granulomas of Mice Infected with <i>Mycobacterium tuberculosis</i> Express Molecules Characteristic of Dendritic Cells and Antiapoptotic Markers of the TNF Receptor-Associated Factor Family. <i>Journal of Immunology</i> , 2005, 175, 3873-3881.	0.8	91
48	Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control <i>Mycobacterium tuberculosis</i> infection. <i>Journal of Leukocyte Biology</i> , 2005, 77, 914-922.	3.3	174
49	Dynamics of Macrophage Cell Populations During Murine Pulmonary Tuberculosis. <i>Journal of Immunology</i> , 2003, 171, 3128-3135.	0.8	186
50	In Vivo IL-10 Production Reactivates Chronic Pulmonary Tuberculosis in C57BL/6 Mice. <i>Journal of Immunology</i> , 2002, 169, 6343-6351.	0.8	243
51	Fluorid pulmonary inflammatory responses in mice vaccinated with Antigen-85 pulsed dendritic cells and challenged by aerosol with <i>Mycobacterium tuberculosis</i> . <i>Cellular Immunology</i> , 2002, 220, 13-19.	3.0	27
52	Characterization of Murine Lung Dendritic Cells Infected with <i>Mycobacterium tuberculosis</i> . <i>Infection and Immunity</i> , 2001, 69, 1127-1133.	2.2	147
53	Temporal and Spatial Arrangement of Lymphocytes within Lung Granulomas Induced by Aerosol Infection with <i>Mycobacterium tuberculosis</i> . <i>Infection and Immunity</i> , 2001, 69, 1722-1728.	2.2	181